Avadel Pharmaceuticals — Q3 2018 Earnings Presentation
10 slides from Avadel Pharmaceuticals's earnings presentation, Nov 5, 2018
Slide 1: Q3 2018 Earnings Conference Call
Q3 2018 Earnings Conference Call November 5, 2018
Slide 2: Safe Harbor
Safe Harbor This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project,” “guidance” and similar expre
Slide 3: Non-GAAP Financial Results
Non-GAAP Financial Results *Reconciliations from GAAP to Non-GAAP can be found in the appendix Three Months Ended (in $000s, except for per share amounts) 09/30/18 06/30/18 09/30/17 Total revenues $ 19,826 $ 29,230 $ 39,675 Cost of products 3,120 3,512 3,790 Research and development expenses 11,402
Slide 4: GAAP Financial Results
GAAP Financial Results Three Months Ended (in $000s, except for per share amounts) 09/30/18 06/30/18 09/30/17 Total revenues $ 19,826 $ 29,230 $ 39,675 Cost of products 3,120 3,512 3,790 Research and development expenses 11,402 11,890 8,095 Selling, general and admin expenses 24,829 27,843 11,563 In
Slide 5: Cash Flow Summary
Cash Flow Summary in $000's Nine Months ended September 30, 2018 2017 TOTAL Cash and Marketable Securities Beginning Balance $ 94,075 $ 154,195 Operating cash flows (excl earnouts and interest and tax payments) (36,197) 73,258 Earnout payments (18,615) (28,175) Interest payments (2,965) - Tax paymen
Slide 6: 2018 Guidance
2018 Guidance Current Guidance Previous Guidance Revenue - Total $90M - $105M $90M - $105M Revenue - Noctiva < $5M $5M - $10M SG&A Expense $85M - $95M $80M - $90M R&D Expense $40M - $50M $40M - $50M M Cash Interest Expense $6M $6M Income Tax Benefit – Non-GAAP 0% - 10% 0% - 10% 2018 Updated Guidance
Slide 7: Appendix
tv Avadel APPENDIX
Slide 8: GAAP to Non-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations (in $000s, except for per share amounts) GAAP to Non-GAAP adjustments for the three months ended September 30, 2018 Exclude Include Contingent Equity securities Amortization of related party Contingent Foreign unrealized debt discount payable related party Intangible
Slide 9: GAAP to Non-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations (in $000s, except for per share amounts) GAAP to Non-GAAP adjustments for the three months ended June 30, 2018 Exclude Include Contingent Amortization of related party Contingent Foreign Equity Securities debt discount payable related party Intangible asset exchange
Slide 10: GAAP to Non-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations (in $000s, except for per share amounts) GAAP to Non-GAAP adjustments for the three months ended September 30, 2017 Exclude Include Contingent related party Contingent Foreign payable related party Intangible asset exchange (loss) Restructuring fair value payable Tot
Avadel Pharmaceuticals — Q3 2018 Earnings Presentation on 6ix